Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation.

摘要: Objectives Mycophenolate mofetil (MMF) is used in liver transplantation (LTx) to reduce rejection, nephrotoxicity, neurotoxicity, and the need for steroids. Lower trough concentrations bioavailability have been reported with oral MMF first week after LTx. These parameters improve month postoperatively. Previously published studies formulations of MMF. In this study, we sought examine survival, nephrotoxicity rates using IV live donor (LDLT). Patients methods Twenty-eight patients (mean age, 50.1 years; 15 men, 13 women) were examined between January 2000 2004 a mean follow-up 17 months renal function. Results Four died at 2, 5, 8, 18 LDLT from sepsis (n = 3) recurrent hepatocellular carcinoma 1). There no retransplants; hence, patient graft survival same (82.4%). Three (10.7%) experienced acute cellular rejection requiring treatment. The serum creatinine level prior was 0.9 +/- 0.4 mg/dL, which remained stable throughout study. One required hemodialysis during perioperative period 8 days. Conclusions current demonstrate new strategy administration low-dose tacrolimus that provides lower better preservation function, one tolerated compared historical treatments